Through the takeover DHL Supply Chain expands its Life Sciences and Healthcare capabilities and abilities to deliver integrated, end-to-end solutions across the full life sciences and healthcare company in 2025, value chain through the final mile. It is already the second acquisition of a healthcare specialist in 2025, following DHL Supply Chain’s purchase of CryoPDP, a leader in clinical trial logistics.
The strategic acquisition will further expand DHL’s healthcare logistics portfolio enhancing the company’s ability to deliver integrated, time-critical solutions across every stage of the Life Science & Healthcare sector. LSHC currently contributes €5 billion to DHL’s global revenue, underscoring its significance in the Group’s growth strategy.
To meet the demand, in APR25, DHL Supply Chain launched a new Pharma Hub in Singapore, a dedicated facility for pharmaceutical logistics. The €10 million facility is part of DHL Group’s €500 million investment into Asia Pacific to bolster its Life Sciences and Healthcare (LSHC) infrastructure across all business units. This strategic initiative reflects DHL Group’s global focus on the healthcare sector as part of its Strategy 2030, which introduced the new “DHL Health Logistics” sector brand to drive cross-divisional growth. “The life sciences and healthcare sector is projected to grow at a compound annual growth rate of 11% through 2030. Specialty pharmacy already accounts for approximately 50% of total prescription drug spending in the U.S., and the number of patients served by specialty pharmacies grew by 12% between 2018 and 20221.” The executive went on to say: “Increasing demand for specialty pharma and healthcare solutions presents significant opportunities for DHL to leverage its scale, expertise, and commitment to operational excellence. With this acquisition, we are expanding our healthcare logistics capabilities, attracting a new segment of healthcare customers, and reinforcing our position as a trusted partner in building resilient and connected healthcare supply chains,” stated Mark Kunar, CEO of DHL Supply Chain North America. Drew Kronick, Founder, CEO & Managing Partner of SDS Rx noted: “Our mission is to enhance the quality of patient care with every delivery. As the demand for last mile delivery in healthcare continues to grow, we understand the importance of aligning with a partner who shares our patient-first commitment. Partnering with DHL represents a meaningful step forward, combining our strengths to improve the precision, reliability, and speed of delivery to patients most in need.”
